Building A Biotech: Industry Veteran Moroney Reflects
Simon Moroney has led the German antibody technology biotech MorphoSys since 1992. Having taken the decision to retire just as the firm is entering the next phase in its evolution, he explains to Scrip why the time is right.
You may also be interested in...
Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.
MorphoSys CEO Simon Moroney tells Scrip that sales of Tremfya in the US and now Europe as a treatment for plaque psoriasis will help fund the German biotech's nascent proprietary pipeline.
Roche is taking a punt on a new Phase III trial with gantenerumab in patients with mild Alzheimer's despite ending one called SCarlet RoAD in similar patients just over two years ago.